NVCT Stock Analysis: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$17.55
1.02 (6.17%)
▲
5d:
+57.4%
30d:
+60.42%
90d:
+112.47%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 04, 2026
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: NVCT is 34.9% above its trading range ($13.01). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: NVCT is 34.9% above its trading range ($13.01). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $17.55, which is considered extended relative to its 30-day fair value range of $8.99 to $13.01.
Technical Outlook: Technically, NVCT is in a uptrend. The price is approaching resistance at $10.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: NVCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NVCT is in a uptrend. The price is approaching resistance at $10.50. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.2% recently.
Market Sentiment: NVCT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$8.99 -
$13.01
Company Quality Score
58/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
41.7%
All Signals
- BEARISH: Price significantly overextended (+34.9% above its trading range)
- BEARISH: Options expensive (IV 100th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.2%)
- NEUTRAL: Near Wall St target ($17.40)
Trading Range Analysis
30-Day Trading Range
$8.99 -
$13.01
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$5.13
(29.2%)
Support & Resistance Levels
Support Level
$9.22
Resistance Level
$10.50
Current Trend
Uptrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.42
Wall Street Target
$17.40
(+5.3%)
Share & Embed Analysis
Last updated: June 23, 2026 3:52 PM ET
Data refreshes hourly during market hours. Next update: 4:52 PM
Data refreshes hourly during market hours. Next update: 4:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
MNMD
Mind Medicine Inc |
STRONG BUY
11 analysts |
$29 | 62 BUY |
|
ALLO
Allogene Therapeutics Inc |
STRONG BUY
14 analysts |
$8 | 60 HOLD |
